A Phase 2 interventional study of HKI-272 and Surgical Resection in Breast Cancer, sponsored by Dana-Farber Cancer Institute. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing neratinib in Breast Neoplasms — 6 open to participants now, 8 under way, none of them phase 3. neratinib · Breast Neoplasms.
Among the 39 studies testing neratinib in Breast Neoplasms, this one is the 12th largest by enrollment, is one of 2 that started in 2012, is one of 23 in phase 2, and was the 16th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →6 of the 39 studies testing neratinib in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70 · Women only
Baylor Research Institute · Sites in United States
Ages 18+ · Women only
University Health Network, Toronto · Sites in Canada
Ages 18+
Ruth O'Regan · Sites in United States
Ages 18+
QuantumLeap Healthcare Collaborative · Sites in United States
Ages 18+
By country, each count listing its studies:
neratinib: first FDA approval 2017 (NERLYNX), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 31 · Phase 3 3
First in 2003; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 39 interventional studies. Of the 27 that completed or were terminated, 21 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 39 have an industry lead sponsor. The 10 most frequent:
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
142 studies in Breast Neoplasms by Dana-Farber Cancer Institute: 15 open now, 43 under way, none of them phase 3. Of 95 finished, 45 (47%) have results posted.
Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, this one is the 26th largest by enrollment of the 132 interventional ones that give a count, is one of 9 that started in 2012, is one of 56 in phase 2, and was the 37th registered.
Dana-Farber Cancer Institute’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing neratinib in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT06008275Baylor Research InstituteNeratinib in Combination With Ruxolitinib in Patients With mTNBC | 2027-06 |
| NCT05388149University Health Network, TorontoKadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing neratinib in Breast Neoplasms, from their registry updates:
Among Dana-Farber Cancer Institute’s 142 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2).
In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.
Subjects will receive neratinib and a drug-dosing calendar for each treatment cycle. This drug is given orally on a daily basis, continuously. Each treatment cycle will last for 4 weeks during which time the subject will be taking neratinib every day.
After the final dose of the study drug:
You will have a follow-up visit one month after coming off study treatment. During that visit, you will have a physical examination, functional assessment, assessment of any toxicities and current medications, and a neurological examination. If you continue to have ongoing toxicity related to your study treatment, we will continue to follow you until this toxicity resolves. In addition, we will collect about 5-6 tablespoons of blood for research and to measure if a marker for your particular breast cancer exists.
We would like to keep track of your medical condition for up to two years after you stop the study treatment. If you are not seen in follow-up at your participating center (where you enrolled on the study), we would like to follow you by calling you on the telephone or by sending you a letter once a year to see how you are doing. We may also contact your doctor once every 6 months to see how you are doing. Keeping in touch with you and checking your condition every year helps us look at the long-term effects of the research study. If you do not wish to be contacted after you stop the study treatment, you must notify the research study staff of your withdrawal of consent for follow-up
Inclusion Criteria:
Patients with progressive disease (Cohort 1):
Patients with with operable disease (Cohort 2):
Patient Cohort 3:
-In cohort 3, eligible patients must have measurable Central Nervous System disease. Cohort 3a will have participants with no prior lapatinib therapy. Cohort 3b will have had prior lapatinib therapy.
Exclusion Criteria:
Patient Cohort 4:
- In cohort 4, eligible patients must have measurable Central Nervous System disease. Cohort 4a will have participants with previously untreated brain metastases. Cohort 4b will have participants with progressive brain metastases. Cohort 4c will have participants will have progressive brain metastases and prior T-DM1
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients With Progressive Brain Metastases Intervention: HKI-272 (Neratinib)340 mg orally, once daily.
Drug: HKI-272
Patients Who Are Candidates For Craniotomy. Intervention: HKI-272 (Neratinib) 240 mg orally, once daily. Surgical resection (biopsy). Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
Procedure: Surgical Resection
Cohort 3a will be made up of participants with No Prior Lapatinib Treatment. They will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest. Cohort 3b will be made of of participants with Prior Lapatinib Treatment. Cohort 3b participants will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.
Drug: Capecitabine
Cohort 4a will be made up of participants with previously untreated brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks. Cohort 4b will be made up of participants with progressive brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks. Cohort 4c will be made up of participants with progressive brain metastases and prior T-DM1. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.
Drug: HKI-272 · Drug: Ado-Trastuzumab Emtansine
240 mg orally, once daily
Also known as: Neratinib
Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
Also known as: Biopsy
750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
Also known as: Xeloda
160 mg orally, once daily
Also known as: Neratinib
3.6 mg/kg IV every 3 weeks
Also known as: T-DM1
Objective Response Rate Per Composite Response Criteria
Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on composite criteria, reported separately in Cohorts 1, 3A, 3B. For the volumetric criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions; stable or decreasing steroid dose; stable or improved neurological symptoms. An objective PR by volumetric criteria will be defined as the following: At least a 50% decrease in the sum volume of CNS target lesions, taking as reference the baseline sum volume sustained for at least 4 weeks; no new lesions; stable or decreasing steroid dose; stable or improved neurological symptoms.
Time frame: 2 years
Objective Response Rate Per RANO-BM Criteria
Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on RANO-BM criteria, reported separately in Cohorts 4A, 4B, and 4C. For the RANO-BM criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. An objective PR by RANO-BM criteria will be defined as the following: At least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD sustained for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically.
Time frame: 2 years
Progression-Free Survival
Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. A participant was considered to have an event if they had a CNS progression (defined by RANO-BM criteria for Cohort 4A, 4B, 4C, or defined by composite/volumetric criteria for Cohort 1 and Cohorts 3A and 3B), if they a non-CNS progression as defined by RECIST v1.1 criteria, or if they died without a progression within two cycle lengths (42 days) after their last scan date. Participants alive without disease progression are censored at the date of their last disease evaluation.
Time frame: Assessed from date of first treatment until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years
Overall Survival
Overall survival (OS) is the defined as the duration of time from the date of trial registration to death.
Time frame: Assessed from date of trial registration until the date of death from any cause, up to 5 years
CNS Response by Macdonald Criteria (Bidirectional Criteria)
Defined as either a complete or partial response based on the Macdonald criteria. In the Macdonald response criteria, a complete response (CR) is defined as: disappearance of all enhancing tumor on consecutive CT or magnetic resonance imaging (MRI) scans at least 1 month apart, off steroids, and neurologically stable or improved. A partial response (PR) is defined as: at least 50% reduction in size of enhancing tumor on consecutive CT or MRI scans at least 1 month apart, steroids stable or reduced, and neurologically stable or improved. Reported for Cohort 1 only.
Time frame: 2 years
Reason for Subject Being Taken Off Study Treatment
Reason for subject being taken off study treatment: CNS progression, non-CNS progression, both CNS and non-CNS progression, or reason other than progression such as toxicity or physician decision. For subjects who came off treatment for progression, this outcome describes their first site of disease progression (CNS, non-CNS, or both).
Time frame: 2 years
Objective Response Based on CNS Composite Criteria for Extension Subgroup of Cohort 1
Assess number of objective responses based on CNS composite criteria for subjects in Cohort 1 who opt to receive trastuzumab and neratinib at the time of non-CNS progression
Time frame: 2 years
Objective Response Rate in CNS by Volumetric Criteria
Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on volumetric criteria, reported separately in Cohorts 4A, 4B, and 4C. For the volumetric criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions. An objective PR by volumetric criteria will be defined as the following: At least a 50% decrease in the sum volume of CNS target lesions, taking as reference the baseline sum volume sustained for at least 4 weeks; no new lesions.
Time frame: 2 years
| Milestone | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C |
|---|---|---|---|---|---|---|---|
| Started | 40 | 5 | 39 | 12 | 6 | 17 | 21 |
| Completed | 40 | 5 | 37 | 12 | 6 | 17 | 21 |
| Not completed | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on composite criteria, reported separately in Cohorts 1, 3A, 3B. For the volumetric criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions; stable or decreasing steroid dose; stable or improved neurological symptoms. An objective PR by volumetric criteria will be defined as the following: At least a 50% decrease in the sum volume of CNS target lesions, taking as reference the baseline sum volume sustained for at least 4 weeks; no new lesions; stable or decreasing steroid dose; stable or improved neurological symptoms.
| percent of participants | Cohort 1 | Cohort 3A | Cohort 3B |
|---|---|---|---|
| Objective Response Rate Per Composite Response Criteria | 7.5 (1.6 to 20.4) | 48.6 (31.9 to 65.6) | 33.3 (9.9 to 65.1) |
Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on RANO-BM criteria, reported separately in Cohorts 4A, 4B, and 4C. For the RANO-BM criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. An objective PR by RANO-BM criteria will be defined as the following: At least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD sustained for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically.
| percent of participants | Cohort 4A | Cohort 4B | Cohort 4C |
|---|---|---|---|
| Objective Response Rate Per RANO-BM Criteria | 33.3 (4.3 to 77.7) | 35.3 (14.2 to 61.7) | 28.6 (11.3 to 52.2) |
Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. A participant was considered to have an event if they had a CNS progression (defined by RANO-BM criteria for Cohort 4A, 4B, 4C, or defined by composite/volumetric criteria for Cohort 1 and Cohorts 3A and 3B), if they a non-CNS progression as defined by RECIST v1.1 criteria, or if they died without a progression within two cycle lengths (42 days) after their last scan date. Participants alive without disease progression are censored at the date of their last disease evaluation.
| months | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C |
|---|---|---|---|---|---|---|---|
| Progression-Free Survival | 1.9 (1.8 to 3.5) | 2.37 (2.07 to NA) | 5.5 (4.6 to 8.1) | 3.1 (1.97 to NA) | 5.26 (4.47 to NA) | 4.11 (2.69 to NA) | 4.14 (2.73 to 6.34) |
Overall survival (OS) is the defined as the duration of time from the date of trial registration to death.
| months | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C |
|---|---|---|---|---|---|---|---|
| Overall Survival | 8.7 (4.9 to 15.1) | NA (6.24 to NA) | 13.3 (10.97 to NA) | 15.1 (7.0 to NA) | 30.16 (21.85 to NA) | 23.29 (17.64 to NA) | 20.86 (14.92 to NA) |
Defined as either a complete or partial response based on the Macdonald criteria. In the Macdonald response criteria, a complete response (CR) is defined as: disappearance of all enhancing tumor on consecutive CT or magnetic resonance imaging (MRI) scans at least 1 month apart, off steroids, and neurologically stable or improved. A partial response (PR) is defined as: at least 50% reduction in size of enhancing tumor on consecutive CT or MRI scans at least 1 month apart, steroids stable or reduced, and neurologically stable or improved. Reported for Cohort 1 only.
| percent of participants | Cohort 1 |
|---|---|
| CNS Response by Macdonald Criteria (Bidirectional Criteria) | 10.0 (2.8 to 23.7) |
Reason for subject being taken off study treatment: CNS progression, non-CNS progression, both CNS and non-CNS progression, or reason other than progression such as toxicity or physician decision. For subjects who came off treatment for progression, this outcome describes their first site of disease progression (CNS, non-CNS, or both).
| Participants | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C |
|---|---|---|---|---|---|---|---|
| CNS and Non-CNS Progression | 3 | 0 | 3 | 1 | 0 | 0 | 3 |
| CNS Progression | 29 | 2 | 23 | 8 | 3 | 11 | 12 |
| Non-CNS Progression | 2 | 0 | 0 | 0 | 1 | 0 | 3 |
| Patient Withdrew for Other Reasons | 0 | 0 | 1 | 0 | 1 | 1 | 2 |
| Physician Discretion | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Unacceptable Toxicity | 6 | 0 | 8 | 0 | 1 | 4 | 0 |
| Subject remained on study treatment at time of evaluation | 0 | 1 | 1 | 2 | 0 | 1 | 0 |
| Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Other off treatment reason | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
Assess number of objective responses based on CNS composite criteria for subjects in Cohort 1 who opt to receive trastuzumab and neratinib at the time of non-CNS progression
| Participants | Cohort 1 |
|---|---|
| Objective Response Based on CNS Composite Criteria for Extension Subgroup of Cohort 1 | 0 |
Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on volumetric criteria, reported separately in Cohorts 4A, 4B, and 4C. For the volumetric criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions. An objective PR by volumetric criteria will be defined as the following: At least a 50% decrease in the sum volume of CNS target lesions, taking as reference the baseline sum volume sustained for at least 4 weeks; no new lesions.
| percent of participants | Cohort 4A | Cohort 4B | Cohort 4C |
|---|---|---|---|
| Objective Response Rate in CNS by Volumetric Criteria | 50.0 (11.8 to 88.2) | 29.4 (10.3 to 56.0) | 23.8 (8.2 to 47.2) |
Collected over All-Cause Mortality was assessed up to 5 years; all adverse events were collected up to 4 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 34/40 (85%) | 1/40 (2.5%) | 38/40 (95%) |
| Cohort 2 | 2/5 (40%) | 0/5 (0%) | 5/5 (100%) |
| Cohort 3A | 21/37 (56.8%) | 0/37 (0%) | 35/37 (94.6%) |
| Cohort 3B | 6/12 (50%) | 0/12 (0%) | 12/12 (100%) |
| Cohort 4A | 3/6 (50%) | 0/6 (0%) | 6/6 (100%) |
| Cohort 4B | 8/17 (47.1%) | 1/17 (5.9%) | 17/17 (100%) |
| Cohort 4C | 11/21 (52.4%) | 0/21 (0%) | 21/21 (100%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C |
|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/40 | 0/5 | 0/37 | 0/12 | 0/6 | 1/17 | 0/21 |
| Intracranial hemorrhageNervous system disorders | 0/40 | 0/5 | 0/37 | 0/12 | 0/6 | 1/17 | 0/21 |
| DiarrheaGastrointestinal disorders | 1/40 | 0/5 | 0/37 | 0/12 | 0/6 | 0/17 | 0/21 |
| Event | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C |
|---|---|---|---|---|---|---|---|
| ColitisGastrointestinal disorders | 1/40 | 1/5 | 1/37 | 11/12 | 6/6 | 10/17 | 1/21 |
| DiarrheaGastrointestinal disorders | 32/40 | 1/5 | 32/37 | 8/12 | 1/6 | 4/17 | 17/21 |
| ConstipationGastrointestinal disorders | 13/40 | 1/5 | 8/37 | 1/12 | 1/6 | 13/17 | 16/21 |
| FatigueGeneral disorders | 20/40 | 2/5 | 2/37 | 1/12 | 4/6 | 1/17 | 9/21 |
| VomitingGastrointestinal disorders | 13/40 | 1/5 | 5/37 | 5/12 | 3/6 | 11/17 | 9/21 |
| VomitingGastrointestinal disorders | 8/40 | 1/5 | 23/37 | 5/12 | 3/6 | 9/17 | 9/21 |
| AnemiaBlood and lymphatic system disorders | 2/40 | 3/5 | 4/37 | 2/12 | 2/6 | 2/17 | 3/21 |
| Blood and lymphatic system disorders - Other, specifyBlood and lymphatic system disorders | 1/40 | 3/5 | 1/37 | 1/12 | 2/6 | 1/17 | 1/21 |
| Thrombotic thrombocytopenic purpuraBlood and lymphatic system disorders | 1/40 | 3/5 | 1/37 | 1/12 | 2/6 | 1/17 | 1/21 |
| BloatingGastrointestinal disorders | 2/40 | 3/5 | 1/37 | 3/12 | 1/6 | 1/17 | 3/21 |
Baseline characteristics reported for the subjects who completed the study, defined as all subjects who received at least one dose of study treatment.
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 50 (34 to 69) | 43 (27 to 45) | 54 (31 to 64) | 52.5 (36 to 60) | 51 (43 to 65) | 48 (41 to 59) | 47 (34 to 67) | 50 (27 to 69) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 39 | 5 | 37 | 12 | 6 | 17 | 20 | 136 |
| Male | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 6 |
| Not Hispanic or Latino | 34 | 5 | 34 | 11 | 5 | 14 | 20 | 123 |
| Unknown or Not Reported | 3 | 0 | 2 | 0 | 0 | 3 | 1 | 9 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C | Total |
|---|---|---|---|---|---|---|---|---|
| Race — White | 34 | 5 | 32 | 7 | 4 | 14 | 20 | 116 |
| Race — Black or African American | 2 | 0 | 1 | 2 | 1 | 0 | 1 | 7 |
| Race — Asian | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 5 |
| Race — Other or More than One Race | 2 | 0 | 2 | 3 | 1 | 2 | 0 | 10 |
| Site of Metastatic Disease: Central Nervous System (CNS) Parenchymal(Participants) | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C | Total |
|---|---|---|---|---|---|---|---|---|
| Yes | 40 | 5 | 37 | 12 | 6 | 17 | 21 | 138 |
| No | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Site of Metastatic Disease: CNS Leptomeningeal(Participants) | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C | Total |
|---|---|---|---|---|---|---|---|---|
| Yes | 4 | 1 | 2 | 1 | 0 | 1 | 2 | 11 |
| No | 36 | 4 | 35 | 11 | 6 | 16 | 19 | 127 |
| Unknown/Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Site of Metastatic Disease: Lung/Pleural(Participants) | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C | Total |
|---|---|---|---|---|---|---|---|---|
| Yes | 15 | 0 | 9 | 4 | 1 | 3 | 6 | 38 |
| No | 25 | 5 | 28 | 8 | 5 | 14 | 15 | 100 |
| Site of Metastatic Disease: Breast or Chest Wall(Participants) | Cohort 1 | Cohort 2 | Cohort 3A | Cohort 3B | Cohort 4A | Cohort 4B | Cohort 4C | Total |
|---|---|---|---|---|---|---|---|---|
| Yes | 2 | 0 | 6 | 1 | 2 | 5 | 1 | 17 |
| No | 38 | 5 | 31 | 11 | 4 | 12 | 20 | 121 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Feb 2012 to primary completion in Feb 2023, 132 months.
Results were first posted in May 2024, 1 year 3 months after primary completion.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 132 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Neratinib · Capecitabine
Dana-Farber Cancer Institute →